Phase 1/2b study of Ibrutinib with Carlfizomib with R/R Myeloma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pharmacyclics, Inc.
Start Date
January 20, 2013
End Date
September 15, 2021
Administered By
Duke Cancer Institute
Awarded By
Pharmacyclics, Inc.
Start Date
January 20, 2013
End Date
September 15, 2021